FAK activation was only partially blocked by Dasatinib (ranging from 40–60%) while Src activation was completely blocked at the same dose (such as 10 nM) (Fig. 5A), suggesting that in pancreatic cancer cells FAK activation is not totally dependent upon Src. The gene discussed is PTK2; the disease is pancreatic neoplasm.